Results 251 to 260 of about 75,890 (310)

Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. [PDF]

J Immunother Cancer
Geboers B, Timmer F, Vos D, Scheffer H, Bakker J, Ruarus A, Vroomen L, Stam A, Lougheed S, Schouten E, Puijk R, van den Tol P, Lagerwaard F, de Vries J, Bruynzeel A, Meijerink M, de Gruijl T.   +16 more
europepmc   +1 more source

Malignant Proliferating Trichilemmal Tumor: A Rare Case Report and Review of Literature

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT This case shows the rarity of Malignant Proliferating Trichilemmal Tumor (MPTT) as well as its aggressive behavior as an adnexal tumor with metastatic potential, requiring early diagnosis and excision. MPTT may occur in younger patients and at atypical sites; malignant transformation should be suspected in long‐standing trichilemmal lesions ...
Chanda Shrestha, Sweta Sah, Deepika Neupane, Sandesh Shah, Smriti Piya, Mohan Bhusal   +5 more
wiley   +1 more source

Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol. [PDF]

BMC Surg
Abreu de Carvalho LF, Gryspeerdt F, Ceelen W, Geboes K, Ribeiro S, Hoorens A, Vandenbussche N, Claes KBM, Lecluyse C, Anisau A, Van Ongeval J, Lybaert W, Triest L, Vervaecke A, Sas S, Claerhout B, Beyls C, Sie M, Berrevoet F.   +18 more
europepmc   +1 more source

Staged Surgical Management of a Colosplenic Fistula Caused by Locally Advanced Splenic‐Flexure Adenocarcinoma

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Colosplenic fistula is a rare complication most commonly associated with colonic lymphoma, adenocarcinoma, and Crohn's disease. In unstable and septic patients, a staged strategy consisting of initial laparoscopic source control and diversion followed by definitive multivisceral resection can balance urgent management of sepsis with adherence ...
Kanhua Yin, Megan E. McNally, Alyssa J. Fesmire   +2 more
wiley   +1 more source

Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions. [PDF]

Front Immunol
Bi Y, Yv H, Ma X, Chen S.
europepmc   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

Irreversible electroporation as an intraoperative adjunctive treatment for locally advanced pancreatic cancer after neoadjuvant therapy: An initial clinical experience. [PDF]

Ann Hepatobiliary Pancreat Surg
Patel A, Lancellotti F, Siriwardena AK, Nadarajah V, de Liguori Carino N, HPB-MRI Collaborative Group.   +5 more
europepmc   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study. [PDF]

Cancers (Basel)
Salas-Salas B, Ferrera-Alayon L, Espinosa-Lopez A, Perez-Rodriguez ML, Afonso AA, Vera-Rosas A, Garcia-Plaza G, Chicas-Sett R, Martinez-Martin MS, Salcedo E, Kannemann A, Lloret-Saez-Bravo M, Lara PC.   +12 more
europepmc   +1 more source

Pathological complete response following neoadjuvant chemotherapy with PD-1 inhibitor for locally advanced pancreatic cancer: case report. [PDF]

J Gastrointest Oncol
Chen J, Wang D, Xiong F, Wu G, Liu W, Wang Q, Kuai Y, Peng F, Chen Y.   +8 more
europepmc   +1 more source